nodes	percent_of_prediction	percent_of_DWPC	metapath
Halofantrine—CYP3A5—Teniposide—lymphatic system cancer	0.248	0.367	CbGbCtD
Halofantrine—CYP3A5—Vincristine—lymphatic system cancer	0.119	0.176	CbGbCtD
Halofantrine—CYP3A4—Cytarabine—lymphatic system cancer	0.0981	0.145	CbGbCtD
Halofantrine—CYP3A4—Teniposide—lymphatic system cancer	0.0966	0.143	CbGbCtD
Halofantrine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0676	0.1	CbGbCtD
Halofantrine—CYP3A4—Vincristine—lymphatic system cancer	0.0465	0.0688	CbGbCtD
Halofantrine—Altered state of consciousness—Vincristine—lymphatic system cancer	0.00788	0.0243	CcSEcCtD
Halofantrine—Haemolytic anaemia—Mechlorethamine—lymphatic system cancer	0.00739	0.0228	CcSEcCtD
Halofantrine—Platelet count decreased—Mitoxantrone—lymphatic system cancer	0.00596	0.0184	CcSEcCtD
Halofantrine—Haemolytic anaemia—Teniposide—lymphatic system cancer	0.00545	0.0168	CcSEcCtD
Halofantrine—Sleep disorder—Fludarabine—lymphatic system cancer	0.005	0.0154	CcSEcCtD
Halofantrine—Haematocrit decreased—Methotrexate—lymphatic system cancer	0.00474	0.0146	CcSEcCtD
Halofantrine—Cerebrovascular accident—Fludarabine—lymphatic system cancer	0.00441	0.0136	CcSEcCtD
Halofantrine—Tinnitus—Mechlorethamine—lymphatic system cancer	0.00431	0.0133	CcSEcCtD
Halofantrine—Stomatitis—Teniposide—lymphatic system cancer	0.0037	0.0114	CcSEcCtD
Halofantrine—Depressed level of consciousness—Carmustine—lymphatic system cancer	0.00368	0.0114	CcSEcCtD
Halofantrine—Abnormal vision—Carmustine—lymphatic system cancer	0.00333	0.0103	CcSEcCtD
Halofantrine—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00328	0.0101	CcSEcCtD
Halofantrine—Stomatitis—Fludarabine—lymphatic system cancer	0.00325	0.01	CcSEcCtD
Halofantrine—Cerebrovascular accident—Bleomycin—lymphatic system cancer	0.00324	0.00999	CcSEcCtD
Halofantrine—Anorexia—Mechlorethamine—lymphatic system cancer	0.00313	0.00965	CcSEcCtD
Halofantrine—Chills—Teniposide—lymphatic system cancer	0.00305	0.00943	CcSEcCtD
Halofantrine—Arrhythmia—Teniposide—lymphatic system cancer	0.00304	0.00938	CcSEcCtD
Halofantrine—Visual impairment—Fludarabine—lymphatic system cancer	0.00288	0.0089	CcSEcCtD
Halofantrine—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00285	0.0088	CcSEcCtD
Halofantrine—Chills—Fludarabine—lymphatic system cancer	0.00268	0.00828	CcSEcCtD
Halofantrine—Arrhythmia—Fludarabine—lymphatic system cancer	0.00267	0.00825	CcSEcCtD
Halofantrine—Face oedema—Carmustine—lymphatic system cancer	0.00267	0.00825	CcSEcCtD
Halofantrine—Chest pain—Teniposide—lymphatic system cancer	0.00252	0.00779	CcSEcCtD
Halofantrine—Confusional state—Teniposide—lymphatic system cancer	0.00244	0.00753	CcSEcCtD
Halofantrine—Ill-defined disorder—Fludarabine—lymphatic system cancer	0.00242	0.00746	CcSEcCtD
Halofantrine—Stomatitis—Bleomycin—lymphatic system cancer	0.00238	0.00735	CcSEcCtD
Halofantrine—Malaise—Fludarabine—lymphatic system cancer	0.00235	0.00725	CcSEcCtD
Halofantrine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00232	0.00716	CcSEcCtD
Halofantrine—Anorexia—Teniposide—lymphatic system cancer	0.00231	0.00711	CcSEcCtD
Halofantrine—Cough—Fludarabine—lymphatic system cancer	0.00227	0.00701	CcSEcCtD
Halofantrine—Convulsion—Fludarabine—lymphatic system cancer	0.00226	0.00696	CcSEcCtD
Halofantrine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00224	0.00693	CcSEcCtD
Halofantrine—Myalgia—Fludarabine—lymphatic system cancer	0.00222	0.00684	CcSEcCtD
Halofantrine—Arthralgia—Fludarabine—lymphatic system cancer	0.00222	0.00684	CcSEcCtD
Halofantrine—Discomfort—Fludarabine—lymphatic system cancer	0.00219	0.00676	CcSEcCtD
Halofantrine—Confusional state—Fludarabine—lymphatic system cancer	0.00214	0.00661	CcSEcCtD
Halofantrine—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00213	0.00656	CcSEcCtD
Halofantrine—Decreased appetite—Teniposide—lymphatic system cancer	0.0021	0.00649	CcSEcCtD
Halofantrine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00209	0.00644	CcSEcCtD
Halofantrine—Stomatitis—Carmustine—lymphatic system cancer	0.00208	0.00642	CcSEcCtD
Halofantrine—Rash—Mechlorethamine—lymphatic system cancer	0.00207	0.00638	CcSEcCtD
Halofantrine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00207	0.00638	CcSEcCtD
Halofantrine—Anorexia—Fludarabine—lymphatic system cancer	0.00203	0.00625	CcSEcCtD
Halofantrine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00199	0.00615	CcSEcCtD
Halofantrine—Stomatitis—Vincristine—lymphatic system cancer	0.00198	0.00612	CcSEcCtD
Halofantrine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00198	0.0061	CcSEcCtD
Halofantrine—Chills—Bleomycin—lymphatic system cancer	0.00197	0.00607	CcSEcCtD
Halofantrine—Nausea—Mechlorethamine—lymphatic system cancer	0.00195	0.00601	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00194	0.00598	CcSEcCtD
Halofantrine—Stomatitis—Mitoxantrone—lymphatic system cancer	0.00193	0.00596	CcSEcCtD
Halofantrine—Urticaria—Teniposide—lymphatic system cancer	0.00192	0.00593	CcSEcCtD
Halofantrine—Abdominal pain—Teniposide—lymphatic system cancer	0.00191	0.0059	CcSEcCtD
Halofantrine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00191	0.00589	CcSEcCtD
Halofantrine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00187	0.00577	CcSEcCtD
Halofantrine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00185	0.0057	CcSEcCtD
Halofantrine—Visual impairment—Carmustine—lymphatic system cancer	0.00185	0.00569	CcSEcCtD
Halofantrine—Fatigue—Fludarabine—lymphatic system cancer	0.00183	0.00566	CcSEcCtD
Halofantrine—Constipation—Fludarabine—lymphatic system cancer	0.00182	0.00561	CcSEcCtD
Halofantrine—Ill-defined disorder—Bleomycin—lymphatic system cancer	0.00177	0.00547	CcSEcCtD
Halofantrine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00175	0.00541	CcSEcCtD
Halofantrine—Asthenia—Teniposide—lymphatic system cancer	0.00174	0.00535	CcSEcCtD
Halofantrine—Malaise—Bleomycin—lymphatic system cancer	0.00172	0.00531	CcSEcCtD
Halofantrine—Pruritus—Teniposide—lymphatic system cancer	0.00171	0.00528	CcSEcCtD
Halofantrine—Arrhythmia—Carmustine—lymphatic system cancer	0.00171	0.00528	CcSEcCtD
Halofantrine—Depressed level of consciousness—Methotrexate—lymphatic system cancer	0.00171	0.00526	CcSEcCtD
Halofantrine—Cough—Bleomycin—lymphatic system cancer	0.00167	0.00514	CcSEcCtD
Halofantrine—Diarrhoea—Teniposide—lymphatic system cancer	0.00165	0.00511	CcSEcCtD
Halofantrine—Chest pain—Bleomycin—lymphatic system cancer	0.00163	0.00502	CcSEcCtD
Halofantrine—Myalgia—Bleomycin—lymphatic system cancer	0.00163	0.00502	CcSEcCtD
Halofantrine—Back pain—Carmustine—lymphatic system cancer	0.00161	0.00498	CcSEcCtD
Halofantrine—Discomfort—Bleomycin—lymphatic system cancer	0.00161	0.00496	CcSEcCtD
Halofantrine—Chills—Mitoxantrone—lymphatic system cancer	0.0016	0.00493	CcSEcCtD
Halofantrine—Arrhythmia—Mitoxantrone—lymphatic system cancer	0.00159	0.00491	CcSEcCtD
Halofantrine—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00157	0.00485	CcSEcCtD
Halofantrine—Confusional state—Bleomycin—lymphatic system cancer	0.00157	0.00485	CcSEcCtD
Halofantrine—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00156	0.00481	CcSEcCtD
Halofantrine—Back pain—Vincristine—lymphatic system cancer	0.00154	0.00475	CcSEcCtD
Halofantrine—Vomiting—Teniposide—lymphatic system cancer	0.00154	0.00475	CcSEcCtD
Halofantrine—Asthenia—Fludarabine—lymphatic system cancer	0.00153	0.00471	CcSEcCtD
Halofantrine—Rash—Teniposide—lymphatic system cancer	0.00153	0.00471	CcSEcCtD
Halofantrine—Dermatitis—Teniposide—lymphatic system cancer	0.00152	0.0047	CcSEcCtD
Halofantrine—Headache—Teniposide—lymphatic system cancer	0.00152	0.00468	CcSEcCtD
Halofantrine—Pruritus—Fludarabine—lymphatic system cancer	0.0015	0.00464	CcSEcCtD
Halofantrine—Back pain—Mitoxantrone—lymphatic system cancer	0.0015	0.00463	CcSEcCtD
Halofantrine—Anorexia—Bleomycin—lymphatic system cancer	0.00149	0.00458	CcSEcCtD
Halofantrine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00145	0.00449	CcSEcCtD
Halofantrine—Convulsion—Carmustine—lymphatic system cancer	0.00144	0.00446	CcSEcCtD
Halofantrine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	0.00144	0.00444	CcSEcCtD
Halofantrine—Nausea—Teniposide—lymphatic system cancer	0.00144	0.00443	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00142	0.00438	CcSEcCtD
Halofantrine—Chest pain—Carmustine—lymphatic system cancer	0.00142	0.00438	CcSEcCtD
Halofantrine—Myalgia—Carmustine—lymphatic system cancer	0.00142	0.00438	CcSEcCtD
Halofantrine—Paraesthesia—Bleomycin—lymphatic system cancer	0.0014	0.00432	CcSEcCtD
Halofantrine—Malaise—Mitoxantrone—lymphatic system cancer	0.0014	0.00431	CcSEcCtD
Halofantrine—Convulsion—Vincristine—lymphatic system cancer	0.00138	0.00425	CcSEcCtD
Halofantrine—Confusional state—Carmustine—lymphatic system cancer	0.00137	0.00423	CcSEcCtD
Halofantrine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00135	0.00418	CcSEcCtD
Halofantrine—Myalgia—Vincristine—lymphatic system cancer	0.00135	0.00418	CcSEcCtD
Halofantrine—Cough—Mitoxantrone—lymphatic system cancer	0.00135	0.00417	CcSEcCtD
Halofantrine—Vomiting—Fludarabine—lymphatic system cancer	0.00135	0.00417	CcSEcCtD
Halofantrine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00134	0.00414	CcSEcCtD
Halofantrine—Rash—Fludarabine—lymphatic system cancer	0.00134	0.00414	CcSEcCtD
Halofantrine—Dermatitis—Fludarabine—lymphatic system cancer	0.00134	0.00413	CcSEcCtD
Halofantrine—Headache—Fludarabine—lymphatic system cancer	0.00133	0.00411	CcSEcCtD
Halofantrine—Myalgia—Mitoxantrone—lymphatic system cancer	0.00132	0.00407	CcSEcCtD
Halofantrine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00132	0.00407	CcSEcCtD
Halofantrine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00132	0.00407	CcSEcCtD
Halofantrine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	0.00131	0.00404	CcSEcCtD
Halofantrine—Discomfort—Mitoxantrone—lymphatic system cancer	0.0013	0.00402	CcSEcCtD
Halofantrine—Anaphylactic shock—Vincristine—lymphatic system cancer	0.0013	0.00401	CcSEcCtD
Halofantrine—Anorexia—Carmustine—lymphatic system cancer	0.0013	0.004	CcSEcCtD
Halofantrine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00128	0.00396	CcSEcCtD
Halofantrine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00128	0.00394	CcSEcCtD
Halofantrine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00126	0.0039	CcSEcCtD
Halofantrine—Nausea—Fludarabine—lymphatic system cancer	0.00126	0.0039	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00124	0.00382	CcSEcCtD
Halofantrine—Urticaria—Bleomycin—lymphatic system cancer	0.00124	0.00382	CcSEcCtD
Halofantrine—Anorexia—Vincristine—lymphatic system cancer	0.00124	0.00382	CcSEcCtD
Halofantrine—Paraesthesia—Carmustine—lymphatic system cancer	0.00122	0.00377	CcSEcCtD
Halofantrine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00121	0.00372	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00118	0.00365	CcSEcCtD
Halofantrine—Decreased appetite—Carmustine—lymphatic system cancer	0.00118	0.00365	CcSEcCtD
Halofantrine—Paraesthesia—Vincristine—lymphatic system cancer	0.00117	0.0036	CcSEcCtD
Halofantrine—Constipation—Carmustine—lymphatic system cancer	0.00116	0.00359	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00115	0.00356	CcSEcCtD
Halofantrine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00114	0.0035	CcSEcCtD
Halofantrine—Decreased appetite—Vincristine—lymphatic system cancer	0.00113	0.00348	CcSEcCtD
Halofantrine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00112	0.00346	CcSEcCtD
Halofantrine—Fatigue—Vincristine—lymphatic system cancer	0.00112	0.00346	CcSEcCtD
Halofantrine—Asthenia—Bleomycin—lymphatic system cancer	0.00112	0.00345	CcSEcCtD
Halofantrine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00111	0.00344	CcSEcCtD
Halofantrine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00111	0.00343	CcSEcCtD
Halofantrine—Constipation—Vincristine—lymphatic system cancer	0.00111	0.00343	CcSEcCtD
Halofantrine—Pruritus—Bleomycin—lymphatic system cancer	0.0011	0.0034	CcSEcCtD
Halofantrine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.0011	0.00339	CcSEcCtD
Halofantrine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00109	0.00336	CcSEcCtD
Halofantrine—Constipation—Mitoxantrone—lymphatic system cancer	0.00108	0.00334	CcSEcCtD
Halofantrine—Abdominal pain—Carmustine—lymphatic system cancer	0.00108	0.00332	CcSEcCtD
Halofantrine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00106	0.00328	CcSEcCtD
Halofantrine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00104	0.00322	CcSEcCtD
Halofantrine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00103	0.00319	CcSEcCtD
Halofantrine—Abdominal pain—Vincristine—lymphatic system cancer	0.00103	0.00317	CcSEcCtD
Halofantrine—Urticaria—Mitoxantrone—lymphatic system cancer	0.001	0.0031	CcSEcCtD
Halofantrine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.001	0.00309	CcSEcCtD
Halofantrine—Vomiting—Bleomycin—lymphatic system cancer	0.000991	0.00306	CcSEcCtD
Halofantrine—Rash—Bleomycin—lymphatic system cancer	0.000983	0.00303	CcSEcCtD
Halofantrine—Dermatitis—Bleomycin—lymphatic system cancer	0.000982	0.00303	CcSEcCtD
Halofantrine—Asthenia—Carmustine—lymphatic system cancer	0.000976	0.00301	CcSEcCtD
Halofantrine—Stomatitis—Methotrexate—lymphatic system cancer	0.000963	0.00297	CcSEcCtD
Halofantrine—Asthenia—Vincristine—lymphatic system cancer	0.000932	0.00288	CcSEcCtD
Halofantrine—Diarrhoea—Carmustine—lymphatic system cancer	0.000931	0.00287	CcSEcCtD
Halofantrine—Nausea—Bleomycin—lymphatic system cancer	0.000926	0.00286	CcSEcCtD
Halofantrine—Asthenia—Mitoxantrone—lymphatic system cancer	0.000907	0.0028	CcSEcCtD
Halofantrine—Dizziness—Carmustine—lymphatic system cancer	0.0009	0.00278	CcSEcCtD
Halofantrine—Diarrhoea—Vincristine—lymphatic system cancer	0.000889	0.00274	CcSEcCtD
Halofantrine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.000865	0.00267	CcSEcCtD
Halofantrine—Vomiting—Carmustine—lymphatic system cancer	0.000865	0.00267	CcSEcCtD
Halofantrine—Dizziness—Vincristine—lymphatic system cancer	0.000859	0.00265	CcSEcCtD
Halofantrine—Rash—Carmustine—lymphatic system cancer	0.000858	0.00265	CcSEcCtD
Halofantrine—Dermatitis—Carmustine—lymphatic system cancer	0.000857	0.00264	CcSEcCtD
Halofantrine—Visual impairment—Methotrexate—lymphatic system cancer	0.000855	0.00264	CcSEcCtD
Halofantrine—Headache—Carmustine—lymphatic system cancer	0.000852	0.00263	CcSEcCtD
Halofantrine—Tinnitus—Methotrexate—lymphatic system cancer	0.000827	0.00255	CcSEcCtD
Halofantrine—Vomiting—Vincristine—lymphatic system cancer	0.000826	0.00255	CcSEcCtD
Halofantrine—Rash—Vincristine—lymphatic system cancer	0.000819	0.00253	CcSEcCtD
Halofantrine—Dermatitis—Vincristine—lymphatic system cancer	0.000818	0.00252	CcSEcCtD
Halofantrine—Headache—Vincristine—lymphatic system cancer	0.000814	0.00251	CcSEcCtD
Halofantrine—Nausea—Carmustine—lymphatic system cancer	0.000808	0.00249	CcSEcCtD
Halofantrine—Vomiting—Mitoxantrone—lymphatic system cancer	0.000804	0.00248	CcSEcCtD
Halofantrine—Rash—Mitoxantrone—lymphatic system cancer	0.000798	0.00246	CcSEcCtD
Halofantrine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.000797	0.00246	CcSEcCtD
Halofantrine—Chills—Methotrexate—lymphatic system cancer	0.000796	0.00246	CcSEcCtD
Halofantrine—Headache—Mitoxantrone—lymphatic system cancer	0.000792	0.00244	CcSEcCtD
Halofantrine—Nausea—Vincristine—lymphatic system cancer	0.000771	0.00238	CcSEcCtD
Halofantrine—Nausea—Mitoxantrone—lymphatic system cancer	0.000751	0.00232	CcSEcCtD
Halofantrine—Back pain—Methotrexate—lymphatic system cancer	0.000747	0.0023	CcSEcCtD
Halofantrine—Ill-defined disorder—Methotrexate—lymphatic system cancer	0.000716	0.00221	CcSEcCtD
Halofantrine—Malaise—Methotrexate—lymphatic system cancer	0.000696	0.00215	CcSEcCtD
Halofantrine—Cough—Methotrexate—lymphatic system cancer	0.000674	0.00208	CcSEcCtD
Halofantrine—Convulsion—Methotrexate—lymphatic system cancer	0.000669	0.00206	CcSEcCtD
Halofantrine—Myalgia—Methotrexate—lymphatic system cancer	0.000657	0.00203	CcSEcCtD
Halofantrine—Arthralgia—Methotrexate—lymphatic system cancer	0.000657	0.00203	CcSEcCtD
Halofantrine—Chest pain—Methotrexate—lymphatic system cancer	0.000657	0.00203	CcSEcCtD
Halofantrine—Discomfort—Methotrexate—lymphatic system cancer	0.00065	0.002	CcSEcCtD
Halofantrine—Confusional state—Methotrexate—lymphatic system cancer	0.000635	0.00196	CcSEcCtD
Halofantrine—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.00063	0.00194	CcSEcCtD
Halofantrine—Anorexia—Methotrexate—lymphatic system cancer	0.000601	0.00185	CcSEcCtD
Halofantrine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000574	0.00177	CcSEcCtD
Halofantrine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000566	0.00175	CcSEcCtD
Halofantrine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000555	0.00171	CcSEcCtD
Halofantrine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000548	0.00169	CcSEcCtD
Halofantrine—Fatigue—Methotrexate—lymphatic system cancer	0.000543	0.00168	CcSEcCtD
Halofantrine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000519	0.0016	CcSEcCtD
Halofantrine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000515	0.00159	CcSEcCtD
Halofantrine—Urticaria—Methotrexate—lymphatic system cancer	0.000501	0.00154	CcSEcCtD
Halofantrine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000498	0.00154	CcSEcCtD
Halofantrine—Asthenia—Methotrexate—lymphatic system cancer	0.000452	0.0014	CcSEcCtD
Halofantrine—Pruritus—Methotrexate—lymphatic system cancer	0.000446	0.00138	CcSEcCtD
Halofantrine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000431	0.00133	CcSEcCtD
Halofantrine—Dizziness—Methotrexate—lymphatic system cancer	0.000417	0.00129	CcSEcCtD
Halofantrine—Vomiting—Methotrexate—lymphatic system cancer	0.000401	0.00124	CcSEcCtD
Halofantrine—Rash—Methotrexate—lymphatic system cancer	0.000397	0.00123	CcSEcCtD
Halofantrine—Dermatitis—Methotrexate—lymphatic system cancer	0.000397	0.00122	CcSEcCtD
Halofantrine—Headache—Methotrexate—lymphatic system cancer	0.000395	0.00122	CcSEcCtD
Halofantrine—Nausea—Methotrexate—lymphatic system cancer	0.000374	0.00115	CcSEcCtD
